Scotland Launches New ‘Ultra-Orphan’ Assessment Pathway
Executive SummaryThe Scottish government is launching its new pathway for the assessment of “ultra-orphan” medicines by the HTA body, the Scottish Medicines Consortium, in an effort to speed up access to medicines for patients with very rare diseases
You may also be interested in...
The Scottish Medicines Consortium has recommended EUSA’s ultra-orphan neuroblastoma treatment Qarziba.
Vertex has succeeded in bringing its portfolio-based approach to the pricing and reimbursement of its cystic fibrosis treatments to another market, Denmark. This follows similar deals in Ireland and Sweden.